Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    CA220-008
Show Display Options
Rank Status Study
1 Completed Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: Denenicokin;   Biological: Nivolumab
2 Active, not recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo

Indicates status has not been verified in more than two years